Literature DB >> 31872383

miR-489 suppresses multiple myeloma cells growth through inhibition of LDHA-mediated aerobic glycolysis.

Han Wu1, Xiuhong Wang2, Tingting Wu2, Su Yang2.   

Abstract

BACKGROUND: Dysregulation of miR-489 in human tumors has been widely reported. Lactate dehydrogenase isoform A (LDHA)-mediated aerobic glycolysis participates in proliferation of multiple myeloma (MM) cells.
OBJECTIVE: To investigate whether miR-489 induced MM growth inhibition via targeting to LDHA-mediated aerobic glycolysis.
METHODS: Expression of miR-489 in representative MM cell lines was determined via qRT-PCR (quantitative real-time polymerase chain reaction). MTT (3-(4, 5-di methyl thiazol-2-yl)-2, 5-di phenyl tetrazolium bromide) and colony formation assays were utilized to detect cell viability and proliferation. Effect of miR-489 on aerobic glycolysis was detected via glucose uptake, lactate and ATP production. Binding ability between miR-489 and LDHA was conducted via luciferase activity assay.
RESULTS: MiR-489 was down-regulated in representative MM cell lines. Gain-of functional assays indicated that over-expression of miR-489 decreased cell viability and inhibited cell proliferation of MM cells. Moreover, miR-489 inhibited aerobic glycolysis via decrease of glucose uptake, lactate and ATP production. LDHA was identified as target of miR-489, suggesting a negative correlation between miR-489 and LDHA in MM cells. Mechanically, the inhibition ability of miR-489 on proliferation of MM cells was through inhibition of LDHA-mediated aerobic glycolysis.
CONCLUSIONS: miR-489 inhibited MM tumor growth via LDHA-mediated glycolytic metabolism, suggesting potential therapeutic target ability of miR-489/LDHA for MM.

Entities:  

Keywords:  Aerobic glycolysis; LDHA; Multiple myeloma; Proliferation; miR-489

Mesh:

Substances:

Year:  2019        PMID: 31872383     DOI: 10.1007/s13258-019-00900-z

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  32 in total

1.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

Authors:  Francesca Fornari; Maddalena Milazzo; Pasquale Chieco; Massimo Negrini; George Adrian Calin; Gian Luca Grazi; Daniela Pollutri; Carlo Maria Croce; Luigi Bolondi; Laura Gramantieri
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis.

Authors:  Xiao Yang; Yidong Cheng; Pengchao Li; Jun Tao; Xiaheng Deng; Xiaolei Zhang; Min Gu; Qiang Lu; Changjun Yin
Journal:  Tumour Biol       Date:  2014-09-30

3.  A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.

Authors:  Lenka Besse; Andrej Besse; Max Mendez-Lopez; Katerina Vasickova; Miroslava Sedlackova; Petr Vanhara; Marianne Kraus; Jürgen Bader; Renan B Ferreira; Ronald K Castellano; Brian K Law; Christoph Driessen
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

4.  Introduction to a review series on advances in multiple myeloma.

Authors:  Hervé Avet-Loiseau
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

5.  Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.

Authors:  Huasheng Lu; Robert A Forbes; Ajay Verma
Journal:  J Biol Chem       Date:  2002-04-09       Impact factor: 5.157

6.  Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.

Authors:  Benjamin Kefas; Laurey Comeau; Nicholas Erdle; Emmitt Montgomery; Samson Amos; Benjamin Purow
Journal:  Neuro Oncol       Date:  2010-07-28       Impact factor: 12.300

Review 7.  Novel targeted therapies and combinations for the treatment of multiple myeloma.

Authors:  Amit Agarwal; Daruka Mahadevan
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2013-03-01

8.  Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.

Authors:  Sho Ikeda; Akihiro Kitadate; Fumito Abe; Hirobumi Saitoh; Yoshihiro Michishita; Yoshiaki Hatano; Yoshinari Kawabata; Atsushi Kitabayashi; Kazuaki Teshima; Masaaki Kume; Naoto Takahashi; Hiroyuki Tagawa
Journal:  Cancer Sci       Date:  2017-04-20       Impact factor: 6.716

9.  NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.

Authors:  Zhimin Gu; Jiliang Xia; Hongwei Xu; Ivana Frech; Guido Tricot; Fenghuang Zhan
Journal:  J Hematol Oncol       Date:  2017-01-13       Impact factor: 17.388

10.  Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.

Authors:  Kamila Anna Zub; Mirta Mittelstedt Leal de Sousa; Antonio Sarno; Animesh Sharma; Aida Demirovic; Shalini Rao; Clifford Young; Per Arne Aas; Ida Ericsson; Anders Sundan; Ole Nørregaard Jensen; Geir Slupphaug
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

View more
  9 in total

1.  Curcumin Antagonizes Glucose Fluctuation-Induced Renal Injury by Inhibiting Aerobic Glycolysis via the miR-489/LDHA Pathway.

Authors:  Xiaomei Fu; Jianfang Zhang; Xuanjie Huang; Zhifeng Mo; Ziyang Sang; Wenfei Duan; Wenfeng Huang
Journal:  Mediators Inflamm       Date:  2021-08-18       Impact factor: 4.711

Review 2.  Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.

Authors:  Amro M Soliman; Teoh Seong Lin; Pasuk Mahakkanukrauh; Srijit Das
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

3.  MicroRNA-489-3p plays a significant role in congenital hypothyroidism through regulating neuronal cell apoptosis via targeting translationally controlled tumor protein 1.

Authors:  Qin Liu; Yuehong Li; Yong Zhou
Journal:  Exp Ther Med       Date:  2021-01-20       Impact factor: 2.447

Review 4.  One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.

Authors:  Antonia Kalushkova; Patrick Nylund; Alba Atienza Párraga; Andreas Lennartsson; Helena Jernberg-Wiklund
Journal:  Epigenomes       Date:  2021-10-08

Review 5.  Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma.

Authors:  Alessandro Allegra; Nicola Cicero; Alessandro Tonacci; Caterina Musolino; Sebastiano Gangemi
Journal:  Cancers (Basel)       Date:  2022-03-27       Impact factor: 6.639

Review 6.  Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases.

Authors:  Olívia Fonseca Souza; Ana Flavia Popi
Journal:  Biomedicines       Date:  2022-08-18

Review 7.  MicroRNAs as Regulators of Cancer Cell Energy Metabolism.

Authors:  Natarajaseenivasan Suriya Muthukumaran; Prema Velusamy; Charles Solomon Akino Mercy; Dianne Langford; Kalimuthusamy Natarajaseenivasan; Santhanam Shanmughapriya
Journal:  J Pers Med       Date:  2022-08-18

Review 8.  Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.

Authors:  Inge Oudaert; Arne Van der Vreken; Anke Maes; Elke De Bruyne; Kim De Veirman; Karin Vanderkerken; Eline Menu
Journal:  Exp Hematol Oncol       Date:  2022-09-01

Review 9.  Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Wen-Hong Wang; Xian-Ning Dong; Li-Mei-Li Tian
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.